Q2 saw 5% sales growth and strong cash generation, led by specialty medicines and vaccines. The Accelerate Growth program targets £1.9B in annual savings to fund R&D and protect margins through key LOE periods, while the Nuvalent acquisition expands the oncology pipeline.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.